Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




Oct
24
Today In Oncology
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab in Mycosis Fungoides and Sezary Syndrome
FDA Grants Traditional Approval to Pembrolizumab for TMB-H Solid Tumors
Geographic Distribution of Triple-Negative Breast Cancer Clinical Trials
Financial Incentives Increase Smoking Abstinence Among Those Referred for Lung Cancer Screening
Metastasis-Directed Ablation Does Not Improve Survival Outcomes in Oligometastatic Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo